- Therma Bright (THRM) has submitted an application to the Research Ethics Board for approval of clinical trials of its COVID-19 rapid saliva-based antigen test
- The independent Research Ethics Board (REB) will decide whether or not to approve a clinical study
- The company expects the REB to approve the trials within a week
- Therma will then submit a complete package to Health Canada to conduct the clinical trial
- Therma Bright is down 2.86 per cent on the day, with shares of the company trading at C$0.34 at 11:36am EST
Therma Bright (THRM) has submitted an application for approval to conduct clinical trials of its COVID-19 rapid saliva-based antigen test.
The independent Research Ethics Board (REB) will decide whether or not to approve a clinical study.
The company’s rapid antigen test is designed to detect SARS CoV-2 virus in saliva.
The company expects the REB to approve the trials within a week.
If approved, Therma will then submit a complete package, including the REB review, to Health Canada to conduct the clinical trial.
The data generated from the clinical study will also be used to support Therma’s European Union CE mark submission, which the company expects to submit shortly.
“We are pleased to cross another hurdle in the process to get AcuVid to market. Performance of the test during the development stage has exceeded our expectations. We are in the process of seeking initial product orders, subject to final regulatory approvals and manufacturing scale up,” said Therma Bright CEO Rob Fia.
Therma Bright is a medical device technology company focused on providing consumers and medical professionals with medical devices that address medical and healthcare needs.
Therma Bright is down 2.86 per cent on the day, with shares of the company trading at C$0.34 at 11:36am EST.
